With the firm's lead indication being Alzheimer's disease - described as a not well understood disease affecting an estimated third of the 65+ age population - NeuroDex develops minimally invasive diagnostics for neurodegenerative disorders with a particular focus on ocusing on developing blood-based diagnostic tests for various neurological conditions. As well as one of a kind services for advancing neurological research and development. NeuroDex's technology is based on a unique ability to isolate exosomes derived from neurons (neuronal derived exosomes, or NDE's) and analysis of these. Envisioning a world where effective and preventative treatments for Alzheimer's exist, principals of the firm note that the pharmaceutical industry has struggled to make headway in the Alzheimer's space due - in somemeasure - to a lack of inexpensive, noninvasive diagnostic tools. The Neurodex effort is to bring the power of exosomes to the neurological diagnostic space - advancingthe firm's technology that has the potential to enable early detection, patient stratification, and disease monitoring. Our proprietary neuron-derived exosome isolation technology can be applied across a number of neurological indications. With our technology, a simple blood draw could allow physicians and researchers to open a window into the brain.
